Jun 14, 2023

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

➞

Jun 11, 2023

Launch Conference of MAILISHU, World's Second Prolia® Biosimilar, Held Successfully

➞

May 24, 2023

Mabwell announces NMPA approval of 9MW3811 for IND

➞

May 22, 2023

Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal

➞

May 10, 2023

Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA

➞

Apr 26, 2023

Mabwell's First Self-commercialized Drug Reached its National Logistics Ceremony

➞

Apr 05, 2023

China’s First Nectin-4 Targeted ADC Drug 9MW2821 Clinical Progress Released

➞

Mar 31, 2023

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

➞

Mar 16, 2023

Mabwell's Clinical Trial Application for 9MW3811 Accepted by NMPA

➞

Mar 13, 2023

Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011

➞